Articles tagged with Immune Receptors
Researchers from the Max Planck Institute for Plant Breeding Research have characterized the structures of several powdery mildew effectors, revealing a common scaffold that allows them to evade recognition by plant immune receptors. This discovery provides new insights into the molecular arms race between plants and fungal pathogens.
Researchers developed a novel vaccine against SARS-CoV-2 by selecting antigen variants with low binding affinity, resulting in higher neutralizing antibody concentrations. This design strategy may also improve vaccine efficacy for other coronaviruses and herpes viruses.
Researchers at MIT have developed a novel sensor that can detect immune molecule CXCL12, which plays a crucial role in several human diseases including cancer. The device uses receptor proteins found in cell membranes, making it a potential tool for early screening of hard-to-diagnose cancers.
A groundbreaking study has uncovered potential treatments for inflammatory disorders by targeting specific receptors involved in the immune response. Researchers created mimetic peptides that successfully reduced inflammation in human immune cells and provided significant protection against toxic shock in mice.
Researchers found that BUB1 protein regulates EGFR signaling by reducing receptor internalization, which may lead to new therapeutic interventions for EGFR-driven cancers. The study also showed that BUB1 impacts receptor recycling and degradation, affecting signaling amplitude and duration.
A novel association of t(5;17) with t(8;21) has been reported in an acute myeloid leukemia (AML) patient, resulting in a RUNX1-RUNX1T1 rearrangement. The patient received chemotherapy and stem cell transplantation, highlighting the importance of this rare translocation.
Researchers discovered a novel peptide, T14, that is detectable in human keratinocytes and inversely related to age, with higher levels found in chronically photosensitive individuals. The study suggests that monitoring T14 levels may offer insights into the link between degenerative diseases and epidermal cell profiles.
A team from the University of Ottawa has developed a comprehensive screening platform and cellular interrogation tool to facilitate novel drug discovery targeting various human diseases. The 'Tango-Trio' platform can identify small molecule modulators for orphan GPCRs, which have significant untapped therapeutic potential.
Researchers have identified a unique immune checkpoint receptor, KIR3DL3, found primarily in the intestine and lungs, suggesting its potential as a target for immunotherapies. This discovery could lead to new treatments for diseases such as lung and bowel cancer and autoimmune conditions like IBD.
Researchers establish a direct link between Covid-19 and Alzheimer's disease, attributing the connection to RAS overactivation caused by SARS-CoV-2 virus. This dysfunction leads to increased b-amyloid protein accumulation, impairing brain cell synaptic connections and cognitive functions.
UCF researcher Dr. Justine Tigno-Aranjuez has discovered a new receptor that recognizes house dust mite allergens, opening up potential for broad-spectrum therapy. The finding could lead to improved treatments for common allergies, including asthma.
Researchers developed a bio-sensing technology that measures PD1 ligand functionality to predict patient response to anti-PD1 therapy. This technology enables accurate prediction of patient response and tailoring treatments accordingly, improving cancer patients' lives.
University of Pittsburgh researchers created a universal receptor system allowing T cells to recognize any cell surface target. This enables highly customizable CAR T cell and other immunotherapies for treating cancer and diseases, with potential applications in solid tumors.
Researchers uncover how HIV enters human bodies via dendritic cells using Siglec-1 membrane protein; formation of nanoclusters enhances capture, leading to virus compartment formation. Understanding this process can aid in developing effective treatments for HIV/AIDS.
Human macrophages use Siglec-14 receptors to recognize and engulf carbon nanotubes, leading to inflammation. The discovery could pave the way for developing safer carbon nanotubes and therapies to prevent inflammatory diseases.
Researchers found that probiotic bacteria Lactobacillus reuteri stimulates cancer-killing T cells by secreting indole-3-aldehyde, which activates a receptor in CD8 cells. A diet rich in tryptophan enhances the effect of immunotherapy on shrinking tumors and prolonging survival.
Researchers at Ritsumeikan University have made a breakthrough in understanding how macrophages recognize microplastics, discovering an interaction between aromatic rings that drives this process. The study suggests that while microplastics may not induce acute inflammation, chronic exposure could lead to autoimmune diseases.
Researchers have found a potential treatment for osteoarthritis by targeting the GP130 immune receptor, which causes hyper-inflammation in joints. The new compound R805/CX-011 showed promising results in animal studies, reducing joint pain and stiffness, and may lead to Phase 1 and 2A clinical trials.
A comprehensive analysis of invasive ER+ breast cancers found macrophages as dominant immune cells infiltrating tumors. The study identified distinct immune cell 'neighborhoods' associated with good patient outcomes and highlights the need for tailored immunotherapies targeting macrophages.
Researchers at Arizona State University describe an innovative therapy using transient expression in tobacco plants to produce a monoclonal antibody against SARS-CoV-2. This class 4 mAb provides key advantages over existing treatments, including mutation resistance and universal protection against emerging variants.
Researchers at the University of Virginia Health System have identified a vital contributor to hyperactive immune responses and neuroinflammation in multiple sclerosis. Blocking this regulator alleviated harmful inflammation in lab mice, suggesting a potential therapeutic target for new treatments.
Researchers at Harvard's Wyss Institute developed a method to fine-tune CAR-T cell stimulation using artificial antigen-presenting scaffolds. This approach enhances consistency and potency of resulting CAR-T cell products, allowing for better cancer treatment outcomes.
Researchers identified a protein in lung cells that blocks SARS-CoV-2 infection and forms a natural protective barrier. The discovery opens up an entirely new area of immunology research around LRRC15 and offers promising prospects for developing new drugs to prevent viral infection or treat fibrosis in the lungs.
Researchers highlight CD200's role in regulating immunosuppressive tumor microenvironments and propose alternative strategies for its neutralization. Unbiased genomic- and proteomic-based approaches may help clarify CD200 expression regulation across various human cancers.
Researchers identified a new type of flagellin in the human gut that binds to Toll-like receptor 5 without inducing an inflammatory response. This discovery provides a mechanism for the immune system to tolerate beneficial microbes while remaining responsive to pathogens.
Researchers discovered a cross-species signaling pathway between ticks and mammals that triggers an immune response before bacteria can infect. This pathway integrates immunity with development, providing early warning for tick-borne diseases.
Researchers at University of Nottingham have discovered a new mechanism to block the Mannose Receptor, which is present in key immune cells and can be hijacked by viruses and some cancers. Synthetic glycopolymers have been designed to trap the receptor within the cell, inhibiting its function.
Researchers at UCSF have developed a novel approach to prevent antibodies from triggering immune rejection of engineered therapeutic and transplant cells. By using a decoy receptor, they can capture the antibodies and take them out of circulation before they can kill the therapeutic cells.
Scientists from Trinity College Dublin discovered that Interleukin-37 activates the immune system, contrary to earlier theories. This finding has significant implications for understanding and treating autoimmune disorders and inflammation.
Researchers at UCSF and IBM Research create a predictive model that encodes commands for cells to kill cancer cells. By combining words that guide engineered immune cells, they can predict which elements should be included in a cell to carry out precise behaviors. This advance allows scientists to rapidly design new cellular therapies.
Researchers found that HER2-positive breast cancer patients with high levels of tumour infiltrating lymphocytes in residual disease have significantly shorter overall survival. High levels of TILs are associated with poorer outcomes, while lower levels are linked to improved survival rates.
A team of scientists from The Jackson Laboratory has adapted cancer therapeutic CAR-T cell therapy to eliminate SARS-CoV-2 virus pre- and post-infection in vitro. They have also developed an ACE2-bispecific-based therapy that can target all variants, including Delta and Omicron.
USCF researchers have developed a new approach called CAR Pooling to compare different re-engineered T cells with varying molecular features. The screen revealed new and surprising receptors that make these therapeutic cells more powerful, promising a better treatment for blood cancers.
Scientists have elucidated the exact molecular structure of an IgM-type B cell receptor, revealing its asymmetrical complex with signaling subunits. The discovery provides insights into how the receptor interacts with other molecules and could lead to a better understanding of vaccine development and lymphoma formation.
Researchers decode Sr35 wheat protein's structure and function, revealing its role in protecting Einkorn wheat from Ug99. The discovery provides a crucial tool for improving crop resistance and ensuring global food security.
A team of researchers from Florida Atlantic University and Tel Aviv University are investigating the connection between neuroimmune serotonergic interactions and Alzheimer's-related mood disorders. By studying mice with AD-linked mutations, they aim to determine if immune-serotonin crosstalk plays a role in depressive traits.
A study by Kumamoto University researchers found that a defective isoform of the SIGIRR gene activates an inflammatory pathway associated with cystic fibrosis. This defect leads to decreased expression and function of anti-inflammatory molecules, resulting in severe inflammation.
Researchers uncover crucial role of enzyme NAGK in converting bacterial cell wall component MDP into its phosphorylated form, activating immune receptor NOD2. This process prevents bacteria from entering the intestinal wall and triggering inflammatory responses.
A recent study led by Eliza Loo found that plant immune receptors and signaling components confer salt tolerance even in plants challenged by non-pathogenic microbes. This suggests that plants can sense and initiate adaptive responses to abiotic stresses upon detecting alterations in cues presented by plant-inhabiting microbes.
Researchers captured first image of antigen-bound T-cell receptor complex with bound antigen at atomic resolution. The study reveals no significant structural changes in the receptor after antigen binding, sparking further investigation into the signaling pathway activation mechanism.
A new study by Tokyo University of Science researchers reveals that dendritic cell immunoreceptor (DCIR) plays a crucial role in the development of colorectal tumors. Blocking DCIR may prevent ulcerative colitis and colon cancer, offering a potential therapeutic target for treating these diseases.
Researchers analyze delta variant's biophysical characteristics, revealing unique traits that evade neutralizing antibodies and contribute to severe symptoms. The study sheds light on why vaccinated individuals can still contract the virus and why delta variant hospitalizations are higher than other variants.
The SARS-Arena program identifies conserved peptides in the SARS-CoV-2 virus that could be used to develop vaccines. The peptides are part of the nucleocapsid protein, which is highly expressed upon infection and highly immunogenic.
A team led by Dr. Johan Duchêne investigated commercial antibodies against ACKR1, refuting a previous study that claimed its expression on macrophages and monocytes. The study emphasizes the significance of antibody specificity and demonstrates the importance of publishing corrections in scientific research.
Researchers at Max Planck Institute identified two classes of molecules boosting plant immunity. These compounds drive critical defense-control hubs and could be used as natural immunostimulants for crop diseases.
Researchers at Gladstone Institutes and Stanford University identified key genes linked to T cell exhaustion. They discovered how to block these genes, resulting in healthier T cells and smaller tumors in mice with cancer. This breakthrough may lead to improved immune-based treatments for cancer patients.
A new study published in Nature reveals that a small population of neurons near the base of the brain can induce symptoms of sickness, including fever, appetite loss, and warm seeking behavior. The researchers found these neurons have receptors capable of directly detecting molecular signals from the immune system.
Research reveals distinct cellular receptor mutations influence COVID-19 disease severity, with high-affinity variants associated with increased risk. The study found that these genetic variants lead to an exaggerated immune response and enhanced antibody-dependent activation of killer cells.
A UCLA-led team found that an abnormally suppressed immune system, not a persistently hyperactive one, may be to blame for some cases of long COVID-19. The study suggests boosting immunity in those individuals could be a treatment option.
Researchers at Gladstone Institutes and UC San Francisco have developed a comprehensive rule book for designing therapeutic cells with improved specificity and safety. The new receptor system, dubbed SNIPRs, is small enough for cost-effective engineering into human cells and can detect and respond to even small amounts of its target. T...
Researchers at UC San Diego found that ovarian cancer tumors activate FAK protein to regulate CD155 expression, creating a shield against immune detection and evading treatment. New molecular targets may boost immune response and lead to new combinatorial strategies for this disease.
MIT biological engineers have developed a new technique that allows them to precisely identify interactions between immune cells and their target antigens. This tool, which uses engineered viruses, enables large-scale screens of such interactions and could accelerate the development of more effective vaccines and immunotherapies.
The newly developed COVID vaccine, PreS-RBD, targets the receptor binding domains of SARS-CoV-2 and induces a robust immune response. The vaccine has shown effectiveness in protecting against all known SARS-CoV-2 variants, including omicron, even in individuals who have not previously built up immunity.
Researchers at the University of Bonn have shown how an inhibitor binds to the A2A receptor, a key regulator of the immune system. This discovery could lead to targeted search for molecules that give the innate immune system more punch against cancer and brain diseases.
A UCI-led study reveals how a TREM2 gene mutation in brain microglia immune cells can increase the risk of Alzheimer's disease. The research found that blocking excess calcium accumulation may be an effective way to modulate microglia behavior and fight the disease.
New study reveals that T-cell responses against the SARS-CoV-2 spike protein can predict protection against infection. In healthy individuals, T cells with a specific cytokine profile offered immunity against COVID-19. In contrast, cancer patients showed lower T-cell responses and increased susceptibility to infection.
A new approach for identifying shared patterns in immune cell receptor sequences may help determine if a person has previously been infected or vaccinated against a given pathogen. Researchers have developed software called tcrdist3 to facilitate this process.
Antibodies that mimic the SARS-CoV-2 virus may explain lingering symptoms of long-haul COVID-19 and rare vaccine side effects like allergic reactions and blood-clotting. This theory, based on classic immunological concepts, suggests a cascade of immune responses that can lead to adverse effects.
Researchers found that antihistamines improve responses to immune checkpoint inhibitors in cancer patients, particularly those with pre-existing allergies or high plasma histamine levels. The study suggests targeting the histamine receptor HRH1 may be a useful treatment approach.
A recent study at Tampere University discovered that the expression of an allergy-related receptor chain for proinflammatory IL-13 cytokine protects against experimental skin cancer. The absence of this receptor led to increased regulatory T cells and a suppressed immune response, allowing cancer cells to grow and form tumors.